对帕金森病的药物建议基于症状进展的动态
Minjae Oh1, Hongbum Kim1, Hyo Kyung Lee2
1School of Industrial Management and Engineering, Korea University, Seoul, 02841, Korea.
Scientific reports
|October 24, 2024
概括
这项研究为长期帕金森症提供了新的策略.
科学领域:
- 神经学 神经学
- 计算神经科学是一种神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 对于帕金森病 (PD) 的长期药物管理存在有限的指导.
- 目前的策略往往侧重于初始治疗,而不是持续的调整.
- 有效的长期管理对于改善患者的生活质量至关重要.
研究的目的:
- 根据患者特定的进展模式,为帕金森病制定最佳的药物调整策略.
- 创建决策模型,平衡最大化有利的健康状况,最小化不利的健康状况,同时避免不良影响.
- 提供灵活的临床指导,以便随着时间的推移管理帕金森病的药物治疗.
主要方法:
- 利用了来自帕金森病进展标记计划 (PPMI) 的数据.
- 采用多变量时间序列聚类来识别不同的患者症状进展动态.
- 开发了马尔科夫决策过程 (MDP) 模型来模拟药物调整策略.
主要成果:
- 确定了四个不同的患者群:可取,不可取,运动集中失败和非运动集中失败.
- 开发了两个MDP模型,解决了双重目标:最大限度地提高健康状况,最大限度地减少不良结果.
- 将模型整合到一个框架中,为每个患者状态建议最佳行动和禁忌.
结论:
- 开发的框架为调整帕金森病的药物强度提供了灵活,个性化的指导.
- 这种方法超越了特定的药物处方,以适应性管理策略.
- 这些发现增强了对长期帕金森病护理的临床决策.
相关概念视频
01:24Parkinson's Disease: Treatment
227
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
227
01:15Parkinson's Disease: Overview
486
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
486
01:28Drug Therapy
39
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
39
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
01:26Psychosis: Goals of Pharmacotherapy
104
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
104
01:37Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K